$YDES

YD Bio (YDES) director files Form 3 with no share activity

YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES, indicating no reported purchases, sales, or other insider transactions. The filing lists him as a director, with all transaction counts and share totals recorded as zero. This Form 3 filing confirms no insider trading activity from the specified director.

Original reporting
Published Mar 31, 2026, 5:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 31, 2026, 6:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$YDES
Neutral
high confidence
Mentioned
$YDES
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$YDESNeutralLow
01

Why it matters

The filing indicates no recent insider trading activity, suggesting no immediate insider-driven market movements.

02

Market read

The news has limited relevance to the broader market; it primarily informs about insider activity levels for YD Bio Ltd.

03

What to watch

Insider activity is just one of many indicators; absence of transactions does not necessarily imply company stability or future performance.

Timing: low

Background

This news pertains to insider reporting requirements, which are routine disclosures for publicly traded companies.

Company-level read

Ticker impact

$YDESNeutralHigh confidence
Context

The news pertains directly to YD Bio Ltd (YDES), specifically regarding insider activity.

Expected impact

Minimal to no immediate price movement expected due to lack of insider activity; however, traders should monitor for future filings.

Evidence & confidence

Form 3 filings are standard disclosures that confirm insider activity levels. The absence of transactions indicates no insider-driven trading signals at this time.

Market effects

No significant sector-wide implications as insider activity remains unchanged.

Limited regional impact due to the company's localized insider activity.

Negligible; the news pertains to a specific company's insider filing with minimal broader market influence.

Counterpoint

Some traders might interpret the lack of insider activity as a sign of stability or potential complacency, which could be viewed positively or negatively depending on broader market context.

Key entities

  • YD Bio Ltd

    A biotechnology company listed under ticker YDES.

  • Lee Jerry Yin-Chia

    Director of YD Bio Ltd who filed the Form 3.

Related articles

$YDESMed

YD Bio Ltd (YDES): Financial results for H1 2026

YD Bio Ltd (YDES) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detec

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

$GOOGLMed

Tigress Financial raises Alphabet stock price target on AI growth

Tigress Financial raised Alphabet's (GOOGL) price target to $485 from $415, citing AI-driven growth in Search, Cloud, and YouTube. The firm highlighted strong Q2 results, 20% revenue growth to $445.87B, and a P/E ratio of 17.38. Alphabet's AI investments are expected to boost long-term economic profit growth. Recent product updates include Gemini AI enhancements and new apps.